**Supplemental Table 2.** **LI-RADS v2018 MR report template**

**LI-RADS v2018 MR Report Reader:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Number** |  | **Image number** | |  | **Patient’s name** |  |
| **Date of MR exam** |  | **Age** | |  | **Sex** |  |
| **Location of observation: segment** |  | | | | | |
| **Largest diameter in cm** |  | | | | | |
| **TIV** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know  Location of TIV: | | | | | |
| **LR-1 or LR-2** | ⬜**LR-1** | | ⬜**LR-2** | | | |
| **Possible diagnosis** | ⬜Cyst ⬜Abscess ⬜Hemangioma ⬜DN ⬜AML ⬜Hepatocellular adenoma ⬜FNH ⬜Inflammatory granuloma  ⬜Other: | | | | | |
| **LR-M (malignant but not HCC specific)**  **Possible diagnosis** | ⬜Yes ⬜No ⬜Unsure ⬜Don't know  ⬜iCCA ⬜Metastasis ⬜Other: | | | | | |
| **Rim APHE** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Peripheral washout** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Delayed central enhancement** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Targetoid restriction** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Infiltrative appearance** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Necrosis or severe ischemia** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Nonrim APHE** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Nonperipheral washout** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Enhancing capsule** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Threshold growth** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know  ⬜Nonevaluable, without previous exam | | | | | |
| **Subthreshold growth** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know  ⬜Nonevaluable, without previous exam | | | | | |
| **Corona enhancement** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Fat sparing in solid mass** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know  ⬜Nonevaluable | | | | | |
| **Restricted diffusion (not targetoid)** | ⬜Yes ⬜No ⬜Suspicious ⬜ Don’t know | | | | | |
| **Mild-moderate T2 hyperintensity** | ⬜Yes ⬜No ⬜Don’t know | | | | | |
| **Nodule-in-nodule** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Mosaic architecture** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Blood products in mass** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Iron sparing in solid mass** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know  ⬜Nonevaluable | | | | | |
| **Fat in mass, more than adjacent liver** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know  ⬜Nonevaluable | | | | | |
| **Nonenhancing capsule** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Size stability ≥2 years** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know  ⬜Nonevaluable, without previous exam | | | | | |
| **Size reduction** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know  ⬜Nonevaluable, without previous exam | | | | | |
| **Parallels blood pool enhancement** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Iron in mass, more than liver** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know ⬜Nonevaluable | | | | | |
| **Undistorted vessels** | ⬜Yes ⬜No ⬜Suspicious ⬜Don’t know | | | | | |
| **Marked T2 hyperintensity** | ⬜Yes ⬜No ⬜Don’t know | | | | | |
| **Tiebreaking rule** | ⬜Yes ⬜No ⬜Don’t know | | | | | |
| **LR-3 or LR-4 or LR-5** | ⬜**LR-3** | ⬜**LR-4** | | ⬜**LR-5** | | |
| **Notes:**  1. APHE, arterial phase hyperenhancement; iCCA, intrahepatic cholangiocarcinoma; FNH, focal nodular hyperplasia; DN, dysplastic nodule; AML, angiomyolipoma.  2. Threshold growth definition is ≥50% size increase of a mass in ≤6 months.  3. Subthreshold growth definition is:  • New ≥10 mm observations in ≤24 months;  • ≥100% size increase on imaging exams >6 months apart. | | | | | | |